DeCure for Type III hypersensitivity reaction disease
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for type III hypersensitivity reaction disease — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleType III hypersensitivity reaction disease maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for type iii hypersensitivity reaction disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adrenoceptor beta 3 (ADRB3) — ADRB3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet aledrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9IJE · 2.34 Å · ligand L-EPINEPHRINE (ALE). Experimental structure, not a prediction.
What the evidence adds up to
Hypersensitivity reactions are immunologically based adverse responses to chemicals or medicinal agents, classified as types I to IV. Type III reactions are immune complex mediated, leading to vasculitis, serum sickness, and urticarial rash; drugs associated include quinine, salicylates, and sulphonamides. In living animals, hypersensitivity reactions rarely occur in isolation but combine during an inflammatory response. The clinical relevance of the classification is unclear, and new subtypes have been proposed. Management has primarily consisted of withdrawal of potential offending agents, supportive therapy, and symptomatic management, with targeted pharmacotherapy in specific examples. Avoidance or prevention is not a feasible option given the immunologic and often unpredictable nature of these reactions.
Almost all chemotherapeutic agents can cause hypersensitivity reactions, with increased risk from platinum compounds, taxanes, asparaginase, monoclonal antibodies, and epipodophyllotoxins. Clinical manifestations are variable and unpredictable, affecting skin, pulmonary, cardiac, and gastrointestinal systems. The mechanism is not yet fully understood. Diagnosis is based on signs, symptoms, and skin testing. Management varies with reaction severity, need to continue treatment, and availability of alternatives. Desensitisation protocols are a noteworthy alternative that may allow re-initiation of therapy with the causative agent, but their use should be assessed individually, weighing risks and benefits. A progressive increase in the use of chemotherapeutic agents is expected to increase the incidence of these reactions.
Delayed-type hypersensitivity, or type IV allergic reaction, is mediated by antigen-specific T cells and subclassified into IVa to IVd based on inflammatory cytokines and effectors. Most sensitizing drugs must be metabolized or bioactivated to a chemically reactive form before they can covalently bind to proteins and form antigens, which are then presented to activate epidermal and skin-homing T cells. Different types of cutaneous drug reactions are associated with different subtypes of delayed-type hypersensitivity and various effectors and cytokines. Only a minority of cutaneous drug reactions have a demonstrable link to IgE, with less than 5% having anti-drug antibodies.
Many factors and cell types involved in hypersensitivity reactions have been identified, but much of the regulation of these components and their role in disease are still to be determined. What is still missing is a full understanding of the molecular mechanisms driving type III reactions specifically, validated biomarkers to predict which patients will develop severe reactions, and clinical trial data testing targeted pharmacotherapy for immune complex-mediated disease. Without these, management remains reactive rather than preventive, and desensitisation protocols lack a robust evidence base for most drugs.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Critical Care Medicine · 2010 · 25 citations
Allergic and hypersensitivity reactions in the intensive care unit
AbstractHypersensitivity reactions are defined as immunologically based adverse reactions to chemicals or medicinal agents. These reactions are common in the intensive care unit and can present as a simple, mildly symptomatic rash or as life-threatening anaphylactic reactions. Hypersensitivity reactions have traditionally been classified as types I to IV reactions based on the underlying immune mechanisms, although the clinical relevance of the classification is unclear, and new subtypes to this system have been recently proposed. Given the immunologic and often unpredictable nature of these reactions, avoidance or prevention is not a feasible option. Therefore, management has primarily consisted of withdrawal of potential offending agents, supportive therapy, symptomatic management, and, in some specific examples, targeted pharmacotherapy. This article outlines the background and types of hypersensitivity reactions and provides descriptions and management strategies when applicable to common types of hypersensitivity reactions encountered in the intensive care unit.
Farmacia Hospitalaria · 2012 · 12 citations · open access
Revisión de las reacciones de hipersensibilidad a antineoplásicos
AbstractOBJECTIVE: To review the characteristics and management of hypersensitivity reactions caused by antineoplastic agents. METHOD: We conducted a search in the Pubmed and EMBASE databases for the last 10 years. RESULTS: Almost all chemotherapeutic agents have the potential to cause hypersensitivity reactions, but some groups have been associated with increased risk, such as platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins. The clinical manifestations of these reactions are variable and unpredictable, including symptoms affecting the skin and the pulmonary, cardiac and gastrointestinal systems. The mechanism associated with their development is not yet fully understood. Diagnosis is based on patients' signs and symptoms and skin testing. The management of patients who suffer a hypersensitivity reaction to a chemotherapeutic agent varies with the severity of the reaction, the need to continue treatment, and the availability of alternative therapies. CONCLUSIONS: Due to a progressive increase in the use of chemotherapeutic agents an increased incidence of hypersensitivity reactions is to be expected. Desensitisation protocols are a noteworthy alternative that make it possible to re-initiate patients' therapy with the causative agent of the hypersensitivity reaction. Their use should be assessed individually, weighing risks and benefits.
AbstractExtract Overview Both immune- and non-immune-mediated drug reactions occur. Amongst immune-mediated drug reactions, the type I–IV classification is followed. Type I reactions These are IgE dependent reactions that lead to urticaria, angioedema, and anaphylaxis. Typical drugs that result in Type I reactions include therapeutic peptides. Type II reactions These are cytotoxic hypersensitivity reactions resulting in haemolysis and purpura. Typical drugs resulting in Type II reactions include penicillins, sulphonamides, cephalosporins, and rifampicin. Type III reactions These are immune complex mediated reactions leading to vasculitis, serum sickness and an urticarial rash. Drugs which are known to be associated with immune complex reactions include quinine, salicylates, and sulphonamides. Type IV reactions These reactions are not dose-dependent and usually begin 7–20 days after initiation of therapy, they are the commonest type of hypersensitivity drug reaction. Only a minority of cutaneous drug reactions, however, have a demonstrable link to IgE, with 〈5% having anti-drug antibodies. Drug-induced angioedema
International Journal of Dermatology and Venereology · 2012 · 0 citations
Roles of delayed-type hypersensitivity in the mechanisms of cutaneous drug reactions
AbstractDelayed-type hypersensitivity,also known as type Ⅳ allergic reaction,is mediated by antigen-specific T cells.It is subclassified into four subtypes,i.e.,Ⅳa to Ⅳd,based on inflammatory cytokines and effectors.Most sensitizing drugs must be metabolized or bioactivated to a chemically reactive form before they are able to covalently bind to proteins and form antigens,which are subsequently presented to activate antigen-specific epidermal T cells and skin-homing T cells and to trigger a cutaneous immune response.Different types of cutaneous drug reactions are associated with different subtypes of delayed-type hypersensitivity as well as various effectors and cytokines.
Key words:
Drug reactions; Hypersensitivity, delayed
Oxford University Press eBooks · 2014 · 0 citations
Hypersensitivity
AbstractHypersensitivity reactions are exaggerated responses of various arms of the immune system to antigenic stimulation that have become so exuberant as to damage the host they evolved to protect. The study of hypersensitivity reactions has a long and distinguished history, as an important part of our evolving understanding of the molecular basis of the immune system. Hypersensitivity reactions may be classified as type I, II, III, or IV. This was proposed in the mid-twentieth century and continues to be a useful system, both for research and in relation to disease processes. In living animals hypersensitivity reactions rarely occur in isolation, but are combined with each other during the evolution of an inflammatory response. Natural infections frequently induce both cellular and humoral immunity, and the relative balance of these two arms of the specific immune response is critical in the defence against pathogens. Many of the factors and cell types involved in hypersensitivity reactions have been identified but much of the regulation of these components and their role in disease are still to be determined.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
